デフォルト表紙
市場調査レポート
商品コード
1107141

ウイルス輸送媒体市場 - 世界の見通しと予測(2022年~2027年)

Viral Transport Medium Market - Global Outlook & Forecast 2022-2027

出版日: | 発行: Arizton Advisory & Intelligence | ページ情報: 英文 274 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
ウイルス輸送媒体市場 - 世界の見通しと予測(2022年~2027年)
出版日: 2022年07月27日
発行: Arizton Advisory & Intelligence
ページ情報: 英文 274 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のウイルス輸送媒体の市場規模は、予測期間の2022年~2027年に3.51%のCAGRで拡大すると予測されています。

当レポートでは、世界のウイルス輸送媒体市場について調査し、市場の概要とともに、製品別、使用法別、適応症別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 調査目的

第3章 調査プロセス

第4章 範囲と適用範囲

第5章 レポートの前提と注意事項

第6章 市場概要

第7章 イントロダクション

  • 概要

第8章 市場機会と動向

第9章 市場の成長促進要因

第10章 市場の成長抑制要因

第11章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第12章 製品

  • 市場概要および成長促進要因
  • 市場概要
  • ウイルス輸送媒体
  • ユニバーサル輸送媒体
  • 分子輸送媒体

第13章 使用法

  • 市場概要および成長促進要因
  • 市場概要
  • 診断
  • 前臨床試験

第14章 適応症

  • 市場概要および成長促進要因
  • 市場概要
  • インフルエンザとCOVID-19
  • 単純ヘルペスウイルス
  • 呼吸器合胞体ウイルス(RSV)
  • 水痘帯状疱疹
  • その他

第15章 エンドユーザー

  • 市場概要および成長促進要因
  • 市場概要
  • 試験所
  • 病院、クリニック
  • その他

第16章 地域

第17章 北米

第18章 欧州

第19章 アジア太平洋

第20章 ラテンアメリカ

第21章 中東・アフリカ

第22章 競合情勢

第23章 主要企業のプロファイル

  • BD(BECTON DICKINSON)
  • HARDY DIAGNOSTICS
  • HIMEDIA LABORATORIES
  • LABORATORY CORPORATION OF AMERICA
  • PURITAN MEDICAL PRODUCTS
  • THERMO FISHER SCIENTIFIC
  • VIRCELL

第24章 その他の著名なベンダー

  • AB MEDICAL
  • ACCUGENE USA
  • APICAL SCIENTIFIC
  • AZOOKA LABS
  • BIOMED DIAGNOSTICS
  • BIOBOAVISTA
  • BIOGENEX LABORATORIES
  • BIOLOGIX GROUP
  • BIOCOMMA
  • CHARM SCIENCES
  • CREATIVE LIFE SCIENCES CO. LTD
  • CITOTEST LABWARE MANUFACTURING
  • CPT MEDICAL
  • COPAN DIAGNOSTIC INC.
  • DIASORIN MOLECULAR
  • EKF DIAGNOSTICS HOLDINGS PLC
  • ENSOL BIOSCIENCES
  • GEMINI BIOPRODUCTS
  • GENERAL BIOLOGICS
  • GENTUERI
  • GENESIS LIFETECH MARKETING
  • HAN CHANG MEDIC
  • HEBEI CHAORAN MEDICAL INSTRUMENTS
  • KSL DIAGNOSTICS
  • LUCENCE HEALTH
  • LAUNCHWORKS
  • LIOFILCHEM
  • MEDICAL WIRE & EQUIPMENT
  • MIRACLEAN TECHNOLOGY
  • METADESIGN SOLUTIONS
  • MANILA HEALTHTEK
  • MATTEK
  • NODFORD INTERNATIONAL
  • STARPLEX SCIENTIFIC
  • SANSURE BIOTECH
  • TITAN BIOTECH
  • VEGAS BIOTECH
  • ZYBIO

第25章 レポートの概要

第26章 定量的要約

第27章 付録

図表

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF GLOBAL VIRAL TRANSPORT MEDIUM MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
  • EXHIBIT 3 INCREASING DEMAND FOR VTM DUE TO SURGE IN COVID-19 INFECTION
  • EXHIBIT 4 IMPACT OF LAUNCHES OF NEW PRODUCTS AND ENTRY OF NEW MARKET PLAYERS
  • EXHIBIT 5 IMPACT OF INCREASING PREVALENCE OF INFECTIOUS DISEASES
  • EXHIBIT 6 IMPACT OF SURGE IN COVID-19 INFECTIONS
  • EXHIBIT 7 DAILY CORONAVIRUS CASES 2020-2022 (MILLION)
  • EXHIBIT 8 COVID-19 TEST PER MILLION CASES IN FEB 2022
  • EXHIBIT 9 IMPACT OF INCREASE IN DIAGNOSIS RATES FOR VIRAL INFECTIOUS DISEASES
  • EXHIBIT 10 IMPACT OF VTM SPECIMENS POSE HIGHER BIOHAZARD DURING TRANSPORTATION THAN OTHER SOLUTIONS
  • EXHIBIT 11 IMPACT OF FALSE-NEGATIVE RESULTS IN BORDERLINE CASES
  • EXHIBIT 12 VIRAL TRANSPORT MEDIA: FACTORS AFFECTING NEGATIVE/ FALSE RESULT
  • EXHIBIT 13 IMPACT OF LACK OF ACCESS TO DIAGNOSIS SERVICES IN LMICS
  • EXHIBIT 14 GLOBAL VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 15 FIVE FORCES ANALYSIS 2021
  • EXHIBIT 16 INCREMENTAL GROWTH BY PRODUCTS 2021 & 2027
  • EXHIBIT 17 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2022-2027
  • EXHIBIT 18 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS: INCREMENTAL GROWTH
  • EXHIBIT 19 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS: ABSOLUTE GROWTH
  • EXHIBIT 20 GLOBAL VIRAL TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 21 GLOBAL VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 22 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 23 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 24 GLOBAL TREND IN CASE NOTIFICATION OF PEOPLE NEWLY DIAGNOSED WITH TB 2016-2020 (PER YEAR IN MILLION)
  • EXHIBIT 25 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 26 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 27 INCREMENTAL GROWTH BY USAGE 2021 & 2027
  • EXHIBIT 28 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USES 2022-2027
  • EXHIBIT 29 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE: INCREMENTAL GROWTH
  • EXHIBIT 30 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE: ABSOLUTE GROWTH
  • EXHIBIT 31 GLOBAL DIAGNOSIS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 32 GLOBAL PREVALENCE OF STI VIRAL DISEASES 2020 (MILLION)
  • EXHIBIT 33 GLOBAL DIAGNOSIS USAGE MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 34 GLOBAL PRE-CLINICAL TESTING MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 35 GLOBAL PRE-CLINICAL TESTING MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 36 INCREMENTAL GROWTH BY PRODUCTS 2021 & 2027
  • EXHIBIT 37 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2022-2027
  • EXHIBIT 38 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION: INCREMENTAL GROWTH
  • EXHIBIT 39 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION: ABSOLUTE GROWTH
  • EXHIBIT 41 GLOBAL INFLUENZA & COVID-19 MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 42 GLOBAL INFLUENZA & COVID-19 INDICATION MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 43 GLOBAL HERPES SIMPLEX VIRUS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 44 GLOBAL HERPES SIMPLEX VIRUS INDICATION MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 45 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 46 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 47 GLOBAL VARICELLA-ZOSTER VIRUS MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 48 GLOBAL VARICELLA ZOSTER VIRUS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 49 GLOBAL OTHERS INDICATION MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 50 GLOBAL OTHER VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 51 INCREMENTAL GROWTH BY END-USER 2021 C& 2027
  • EXHIBIT 52 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2022-2027
  • EXHIBIT 53 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER: INCREMENTAL GROWTH
  • EXHIBIT 54 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER: ABSOLUTE GROWTH
  • EXHIBIT 55 GLOBAL LABS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 56 GLOBAL LABS VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 57 GLOBAL HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 58 GLOBAL HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 59 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY OTHER END-USERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 60 GLOBAL OTHERS VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 61 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 62 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2022-2027
  • EXHIBIT 63 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
  • EXHIBIT 64 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
  • EXHIBIT 65 VIRAL TRANSPORT MEDIUM MARKET NORTH AMERICA: KEY COUNTRIES 2019 ($ MILLION)
  • EXHIBIT 66 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 67 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 68 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
  • EXHIBIT 69 US VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 70 CANADA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 71 VIRAL TRANSPORT MEDIUM MARKET EUROPE: KEY COUNTRIES 2019 ($ MILLION)
  • EXHIBIT 72 EUROPE VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 73 EUROPE VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 74 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
  • EXHIBIT 75 UK: VARICELLA AGE-SPECIFIC ANNUAL COMMUNITY INCIDENTS PER 100,000
  • EXHIBIT 76 UK VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 77 FRANCE: AGE-SPECIFIC ANNUAL COMMUNITY INCIDENCE OF VARICELLA PER 100,000
  • EXHIBIT 78 FRANCE VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 79 ITALY: INCIDENCE OF HERPES BY AGE GROUP & GENDER
  • EXHIBIT 80 ITALY VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 81 GERMANY: TOTAL COVID-19 CASES AUG 2021-FEB 2022 (MILLION)
  • EXHIBIT 82 GERMANY VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 83 SPAIN VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 84 VIRAL TRANSPORT MEDIUM MARKET APAC: KEY COUNTRIES 2019 ($ MILLION)
  • EXHIBIT 85 APAC VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 86 APAC VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 87 INCREMENTAL GROWTH IN APAC 2021 & 2027
  • EXHIBIT 88 CHINA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 89 JAPAN VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 90 INDIA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 91 AGE STANDARDIZED HOSPITALIZATION RATE NOTIFIABLE COMMUNICATION DISEASES 2013-2017
  • EXHIBIT 92 AUSTRALIA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 93 SOUTH KOREA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 94 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET: KEY COUNTRIES 2019 ($ MILLION)
  • EXHIBIT 95 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 96 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 97 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
  • EXHIBIT 98 PREVALENCE OF HERPES ZOSTER IN BRAZIL (VIA REGION) 2021
  • EXHIBIT 99 BRAZIL VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 100 MEXICO VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 101 ARGENTINA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 102 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET: KEY COUNTRIES 2019 ($ MILLION)
  • EXHIBIT 103 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 104 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 105 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
  • EXHIBIT 106 TURKEY: INCIDENT RATE OF HERPES ZOSTER WITH RESPECT TO AGE (2011-2019) (PER 100,000 PEOPLE)
  • EXHIBIT 107 TURKEY VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 108 SAUDI ARABIA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 109 SOUTH AFRICA VIRAL TRANSPORT MEDIUM MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 110 THERMO FISHER SCIENTIFIC: ANNUAL REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 111 THERMO FISHER SCIENTIFIC ANNUAL REVENUE BY SEGMENT 2020 (%)

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2021
  • TABLE 3 SOME OF COVID-19 TRANSPORT MEDIA MANUFACTURER AND PRODUCTS
  • TABLE 4 COVID-19 TEST DONE DURING 2020-2022
  • TABLE 5 VIRAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 6 VIRAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 7 UNIVERSAL TRANSPORT MEDIA KIT & MANUFACTURER
  • TABLE 8 UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 9 UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 10 MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 11 MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 12 OVERALL COVID-19 DIAGNOSIS TEST BY REGION IN 2022
  • TABLE 13 VIRAL TRANSPORT MEDIUM DIAGNOSIS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 14 VIRAL TRANSPORT MEDIUM DIAGNOSIS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 15 VIRAL TRANSPORT MEDIUM PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 16 VIRAL TRANSPORT MEDIUM PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 17 VIRAL TRANSPORT MEDIUM INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 18 VIRAL TRANSPORT MEDIUM INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 19 VIRAL TRANSPORT MEDIUM HERPES SIMPLEX VIRUS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 20 VIRAL TRANSPORT MEDIUM HERPES SIMPLEX VIRUS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 21 VIRAL TRANSPORT MEDIUM RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 22 VIRAL TRANSPORT MEDIUM RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 23 VIRAL TRANSPORT MEDIUM VARICELLA-ZOSTER VIRUS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 24 VIRAL TRANSPORT MEDIUM VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 25 OTHER VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 26 OTHER VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 27 LABS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 28 LABS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 29 HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 30 HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 31 OTHER VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 32 OTHER VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 33 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 34 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 35 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 36 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 37 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 ($ MILLION)
  • TABLE 38 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 (%)
  • TABLE 39 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 40 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 (%)
  • TABLE 41 US: MEDICAL DIAGNOSTICS LABS
  • TABLE 42 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 43 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 44 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 45 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 46 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 ($ MILLION)
  • TABLE 47 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 (%)
  • TABLE 48 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 49 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 (%)
  • TABLE 50 APAC VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 51 APAC VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 52 APAC VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 53 APAC VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 54 APAC VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 ($ MILLION)
  • TABLE 55 APAC VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 (%)
  • TABLE 56 APAC VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 57 APAC VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 (%)
  • TABLE 58 CHINA: LABORATORY DETECTION OF ILI SPECIMENS WEEK 15 IN 2019.
  • TABLE 59 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 60 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 61 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 62 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 63 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 ($ MILLION)
  • TABLE 64 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 (%)
  • TABLE 65 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 66 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 (%)
  • TABLE 67 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2021-2027 ($ MILLION)
  • TABLE 68 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2021-2027 (%)
  • TABLE 69 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 70 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 71 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 ($ MILLION)
  • TABLE 72 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 (%)
  • TABLE 73 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 74 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 75 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 76 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 (%)
  • TABLE 77 BD: MAJOR PRODUCT OFFERINGS
  • TABLE 78 HARDY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 79 HIMEDIA LABORATORIES: MAJOR PRODUCT OFFERINGS
  • TABLE 80 LABORATORY CORPORATION OF AMERICA: MAJOR PRODUCT OFFERINGS
  • TABLE 81 PURITAN MEDICAL PRODUCTS: MAJOR PRODUCT OFFERINGS
  • TABLE 82 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
  • TABLE 83 VIRCELL: MAJOR PRODUCT OFFERINGS
  • TABLE 84 AB MEDICAL: MAJOR PRODUCT OFFERINGS
  • TABLE 85 ACCUGENE USA: MAJOR PRODUCT OFFERINGS
  • TABLE 86 APICAL SCIENTIFIC: MAJOR PRODUCT OFFERINGS
  • TABLE 87 AZOOKA LABS: MAJOR PRODUCT OFFERINGS
  • TABLE 88 BIOMED DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 89 BIOBOAVISTA: MAJOR PRODUCT OFFERINGS
  • TABLE 90 BIOGENEX LABORATORIES: MAJOR PRODUCT OFFERINGS
  • TABLE 91 BIOLOGIX GROUP: MAJOR PRODUCT OFFERINGS
  • TABLE 92 BIOCOMMA: MAJOR PRODUCT OFFERINGS
  • TABLE 93 CHARM SCIENCES: MAJOR PRODUCT OFFERINGS
  • TABLE 94 CREATIVE LIFE SCIENCES CO. LTD.: MAJOR PRODUCT OFFERINGS
  • TABLE 95 CITOTEST LABWARE MANUFACTURING: MAJOR PRODUCT OFFERINGS
  • TABLE 96 CPT MEDICAL: MAJOR PRODUCT OFFERINGS
  • TABLE 97 COPAN DIAGNOSTIC INC.: MAJOR PRODUCT OFFERINGS
  • TABLE 98 DIASORIN MOLECULAR: MAJOR PRODUCT OFFERINGS
  • TABLE 99 EKF DIAGNOSTIC: MAJOR PRODUCT OFFERINGS
  • TABLE 100 ENSOL BIOSCIENCES: MAJOR PRODUCT OFFERINGS
  • TABLE 101 GEMINI BIOPRODUCTS: MAJOR PRODUCT OFFERINGS
  • TABLE 102 GENERAL BIOLOGICS: MAJOR PRODUCT OFFERINGS
  • TABLE 103 GENTUERI: MAJOR PRODUCT OFFERINGS
  • TABLE 104 GENESIS LIFETECH MARKETING: MAJOR PRODUCT OFFERINGS
  • TABLE 105 HAN CHANG MEDIC: MAJOR PRODUCT OFFERINGS
  • TABLE 106 HEBEI CHAORAN MEDICAL INSTRUMENTS: MAJOR PRODUCT OFFERINGS
  • TABLE 107 KSL DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 108 LUCENCE HEALTH: MAJOR PRODUCT OFFERINGS
  • TABLE 109 LAUNCHWORKS: MAJOR PRODUCT OFFERINGS
  • TABLE 110 LIOFILCHEM: MAJOR PRODUCT OFFERINGS
  • TABLE 111 MEDICAL WIRE & EQUIPMENT: MAJOR PRODUCT OFFERINGS
  • TABLE 112 MIRACLEAN TECHNOLOGY (MANTACC): MAJOR PRODUCT OFFERINGS
  • TABLE 113 METADESIGN SOLUTIONS: MAJOR PRODUCT OFFERINGS
  • TABLE 114 MANILA HEALTHTEK: MAJOR PRODUCT OFFERINGS
  • TABLE 115 MATTEK: MAJOR PRODUCT OFFERINGS
  • TABLE 116 NODFORD INTERNATIONAL: MAJOR PRODUCT OFFERINGS
  • TABLE 117 STARPLEX SCIENTIFIC: MAJOR PRODUCT OFFERINGS
  • TABLE 118 SANSURE BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 119 TITAN BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 120 VEGAS BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 121 ZYBIO: MAJOR PRODUCT OFFERINGS
  • TABLE 122 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 123 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 124 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 ($ MILLION)
  • TABLE 125 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021-2027 (%)
  • TABLE 126 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 ($ MILLION)
  • TABLE 127 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021-2027 (%)
  • TABLE 128 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 ($ MILLION)
  • TABLE 129 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021-2027 (%)
  • TABLE 130 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 ($ MILLION)
  • TABLE 131 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021-2027 (%)
  • TABLE 132 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 133 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 134 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 135 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 136 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 137 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 138 GLOBAL DIAGNOSIS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 139 GLOBAL DIAGNOSIS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 140 GLOBAL PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 141 GLOBAL PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 142 GLOBAL INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 143 GLOBAL INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 144 GLOBAL HERPES MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 145 GLOBAL HERPES MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 146 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 147 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 148 GLOBAL VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 149 GLOBAL VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 150 GLOBAL OTHER (INDICATIONS) MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 151 GLOBAL OTHER (INDICATIONS) MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 152 GLOBAL LABS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 153 GLOBAL LABS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 154 GLOBAL HOSPITALS & CLINICS MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 155 GLOBAL HOSPITALS & CLINICS MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 156 GLOBAL OTHER INDICATION MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 157 GLOBAL OTHER INDICATION MARKET BY GEOGRAPHY 2021-2027 (%)
目次
Product Code: ARZ220706

The global viral transport medium market is expected to grow at a CAGR of 3.51% during 2022-2027

Viral transport mediums are the medical kits, swabs, and tubes used to collect, preserve, and transport viral specimens for research and diagnostic tests, which exist in several formulations, consisting of a buffered salt solution, a complex source of protein and amino acids, and anti-microbial agents. It preserves virus and is either used for amplification by nucleic acid amplification testing (NAAT) technology or viral culture. It allows research collection, preservation, and transportation of viral specimens, including conventional cell culture methods, molecular biology techniques, and diagnostic tests. The importance of viral transport medium was known globally when a new H1N1 influenza virus was identified, causing the world's first flu pandemic in more than 40 years. Since then, it has been used majorly by hospitals, labs, and academic/research institutes for transporting viral samples across the research and clinical value chain. During the transport, the virus, if present, in the sample specimen should remain intact until the testing is completed.

More recently, the sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits. With the fast spread of the COVID-19 virus, many countries prioritized diagnostic testing for quick diagnosis of the virus. This fuelled the exponential increase in demand for VTM kits for sample collection from suspected COVID-19 patients. Owing to the surge in demand for diagnostic tests and sample collection from people, many vendors increased their production.

They continuously tried to deliver many viral transport media kits to meet the exponential demand for COVID-19 diagnostic tests. In March 2020, increased demand for covid-19 testing led to a global shortage of nasopharyngeal swabs and viral transport medium (VTM) test kits that significantly impacted large-scale testing efforts.

TRENDS ANALYSIS IN THE MARKET

Suddenly increased SARS-COV-2 infection rate drive substantial demand for VTM kits. It resulted in increased manufacturing and manufacturing capacity of the vendors. Most of the leading and emerging companies took part in fulfilling VTM supply across the healthcare system in the world. In 2020, Thermo Fisher Scientific, one of the leading suppliers of viral transport kits, invested around $40 million in Lenexa and Kansas manufacturing facilities to scale up the production of the kits.

The pandemic increased the manufacturing of VTM kits globally and gave emerging market players new opportunities. Several new entries and new products were launched in the same period. Most of the global market players looked for a maximum supply of these kits; on the other side, newcomers entered with new products.

  • In June 2020, India bases IIT Guwahati developed a new VTM product. The product name is SPLID VTM Kit is a unique and world-class affordable solution which are the first-stop source helped in the collection of oral and nasal swabs specimen.
  • In 2021, the leading manufacturing company of viral transport media, Vircell, launched a new VTM kit solution. This product is validated for collecting and preserving viruses such as SARS-COV-2 & influenza A virus.
  • The UK-based company EKF diagnostic launched a new molecular transport media product for influenza and Covid-19 virus collection. It is one of the unique products that novel transport molecular media used for the dual purpose such as covid-19 and influenza sampling and enabled safe sample handling and testing with one sample swab.

VIRAL TRANSPORT MEDIUM MARKET SCENARIO

Viral transport medium kits are constantly in demand due to the increasing prevalence of infectious diseases. Viral infections are one of the major burdens seen in the pandemic period. The rising prevalence of viral infectious diseases enabled the growth of viral transport media kits. Some of the viral infectious diseases are Covid-19, influenza virus, enterovirus D68, herpes, varicella, RSV, etc. In diagnosing the diseases mentioned above, collection of samples, preservation, and transportation is required, whereas VTM kits are the most prominently used solutions by the practitioners. According to the Plos One article 2021, based on studies documented from 2007 to 2020, the overall prevalence of respiratory syncytial virus was around 11%, and adenovirus accounted for 13%. Influenza viral infection accounted high burden worldwide, which required diagnosis and test.

Non-polio enterovirus causes around 10-15 million infection cases annually & on the other side, 10,000 hospitalizations each year in the US. On the other side, herpes is one of the severe viral infectious conditions that demand laboratory testing for diagnosis and cure. It is categorized into the herpes simplex virus type 1 and herpes simplex virus type 2. It is a sexually transmitted infection that is present lifelong. Around 3.7 billion people under 50 suffer from HSV-1 and 491 million from HSV-2 under the age of 15-49-year-old.

The rising covid-19 test across the world accounted high consumption rate of VTM test kits. More than millions of tests were done daily from June 2020 to Jan 2022, which significantly changed the market and delivered a major turning point for market.

On the other side, increasing the diagnosis rate for viral infectious diseases constantly drives the market growth. The increasing diagnosis rate of viral diseases requires laboratory testing of clinical specimens to identify the virus, viral antigens, and antibodies. Last form two decades major revolution was addressed in the virus diagnostic laboratories. Also, the rapid increase in the aging population, rise in the number of people undergoing various voluntary surgeries, and other factors have accelerated the requirement for various diagnostic tests that involve VTM kits. With the rising prevalence of various acute and chronic diseases worldwide, the number of surgeries performed to treat such diseases is also increasing rapidly.

A surge in Mass Testing for COVID-19 & Influenza

The demand for viral transport has increased exponentially during the COVID-19 pandemic. With academic/research institutes intensifying their experiments for developing vaccines and mass testing to stop the spread of COVID-19 globally, vendors have increased their manufacturing capacities and produced billions of VTM kits. Companies focus on innovation and developing kits containing double-ended flocked swabs, vials, antibiotics, and other items that inhibit microbial contamination. In addition, with the continuous increase of seasonal flu cases, manufacturers are also manufacturing viral transport for influenza tests, owing to influenza-related morbidity and mortality in many countries.

MARKET SEGMENTATION:

Product Insights

The global viral transport medium market is segmented into viral transport media, universal transport media, & molecular transport media. In 2021, viral transport media accounted for a revenue share of 46% in the global viral transport medium market and dominated other segments. The universal transport media segment accounted for 34%, and the molecular transport media segment accounted for 20% market share in 2021.

Usage Insights

The global viral transport kit market is segmented into diagnosis and pre-clinical testing. The rising diagnosis rate of covid-19 cases drives significant market growth by diagnosing severe SARS-COV-2 infection. In 2021, the diagnosis segment accounted for a revenue share of 67.44% in the global viral transport media market and showed dominance over the pre-clinical testing segment.

Indication Insights

Global Viral Transport Medium Market by indication is segmented into influenza & covid-19, herpes simplex virus, varicella-zoster virus, respiratory syncytial virus (RSV), and other adenoviruses, rhinoviruses, enteroviruses, parainfluenza viruses, metapneumoviruses, etc. Influenza is one of the common viral infections globally. In the global Viral Transport Medium Market, the influenza& covid-19 indication segment accounted for 73.09% market share in 2021. The higher infection rate of Covid-19 across the world dominated the market with a higher market share.

End-user Insights

Global Viral Transport Medium Market by end-user segmented into the labs, hospitals & clinics, and another end-user segment. In 2021, the lab's segment accounted for a revenue share of 40.30% in the global viral transport media market and dominated to other two segments. An increasing number of microbiology labs, research labs, biotech labs, and pharmaceutical and biotech company/ organizational labs drive viral transport kits' adoption and contribute to the market growth with dominance over other segments.

Segmentation by Products

  • Viral Transport Media
  • Universal Transport Media
  • Molecular Transport Media

Segmentation by Usage

  • Diagnosis
  • Pre-Clinical Testing

Segmentation by Indication

  • Influenza & Covid
  • Herpes Simplex Virus
  • Respiratory Syncytial Virus
  • Varicella Zoster Virus
  • Others

Segmentation by End-User

  • Diagnostic Labs
  • Hospitals & Clinics
  • Others

GEOGRAPHY INSIGHTS

The market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa region. In North America, a high number of laboratory tests were registered during the pandemic, fueling the market growth. On the other side, the presence of biopharma companies, a high number of labs, well-developed healthcare services, and research studies on viral infection drives significant market growth in the region and accounted 33.18% higher market share. Apart from the Covid-19 pandemic burden, other viral infections such as influenza, herpes, varicella, respiratory syncytial virus, and other viral infectious diseases demand the diagnosis where VTM kits play a vital role in the collection, preservation, and transportation of specimens. The rising prevalence of viral infection across the world delivers high demand for VTM kits. Influenza viral infections continue to increase in African, North America, and Asia Pacific regions.

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • France
    • Italy
    • Germany
    • Spain
  • APAC
    • China
    • Japan
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

COMPETITIVE LANDSCAPE

The global viral transport medium market is highly competitive in nature due to the presence of domestic, regional, and international market players. Also, the geographical presence of key market players and their broad distribution channels increases market competitiveness through their major supply, import, and export strategies. The outbreak of the COVID-19 pandemic significantly increased demand for VTM kits, driving high export and import of VTM kits from different countries through major market players. Vendors are increasing efforts to manufacture VTM products as per regulatory bodies' requirements. For instance, Hardy Diagnostics, an FDA-licensed manufacturer of medical devices for microbiological testing, launched the Universal Transport Medium, which is suitable for collection, maintenance, and long-term freeze storage of clinical specimens. Apart from hospital and retail pharmacies, vendors also offer huge volumes of orders from online pharmacies. Hence, they collaborate with e-commerce companies to increase their sales and revenue options.

Key Vendors

  • BD (Beckton Dickinson)
  • Hardy Diagnostics
  • HiMedia Laboratories
  • Laboratory Corporation of America
  • Puritan Medical Products
  • Thermo Fisher Scientific
  • Vircell

Other Prominent Vendors

  • AB Medical
  • AccuGene USA
  • Apical Scientific
  • Azooka Labs
  • Biomed Diagnostics
  • bioBoaVista
  • Biogenex Laboratories
  • Biologix Group
  • Biocomma
  • Charm Sciences
  • Creative Life Sciences Co. Ltd
  • Citotest Labware Manufacturing
  • CPT Medical
  • Copan Diagnostic Inc.
  • Diasorin Molecular
  • EKF Diagnostic
  • Ensol Biosciences
  • Gemini Bioproducts
  • General Biologics
  • Gentueri
  • Genesis Lifetech Marketing
  • Han Chang Medic
  • Hebei Chaoran Medical Instruments
  • KSL Diagnostics
  • Lucence Health
  • LaunchWorks
  • Liofilchem
  • Medical Wire & Equipment
  • Miraclean Technology (Mantacc)
  • MetaDesign Solutions
  • Manila HealthTek
  • MatTek
  • Nodford International
  • Starplex Scientific
  • Sansure Biotech
  • Titan Biotech
  • Vegas Biotech
  • Zybio

KEY QUESTIONS ANSWERED

  • 1. HOW BIG IS THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?
  • 2. WHO ARE THE MAJOR PLAYERS IN THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?
  • 3. WHAT ARE THE GROWTH FACTORS IN THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?
  • 4. WHAT ARE SOME OF THE LATEST TRENDS THAT WILL SHAPE THE FUTURE OF THE GLOBAL VTM MARKET?
  • 5. WHICH REGION IS EXPECTED TO OBSERVE THE LARGEST SHARE IN THE VIRAL TRANSPORT MEDIUM MARKET?

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 OVERVIEW

8 MARKET OPPORTUNITIES & TRENDS

  • 8.1 INCREASING DEMAND FOR VTM DUE TO SURGE IN COVID-19 INFECTION
  • 8.2 LAUNCH OF NEW PRODUCTS AND ENTRY OF NEW MARKET PLAYERS

9 MARKET GROWTH ENABLERS

  • 9.1 INCREASING PREVALENCE OF VIRAL INFECTIOUS DISEASES
  • 9.2 SURGE IN COVID-19 INFECTIONS
  • 9.3 INCREASE IN DIAGNOSIS OF VIRAL INFECTIOUS DISEASES

10 MARKET RESTRAINTS

  • 10.1 VTM SPECIMENS POSE HIGHER BIOHAZARD DURING TRANSPORTATION THAN OTHER SOLUTIONS
  • 10.2 FALSE-NEGATIVE RESULTS IN BORDERLINE CASES
  • 10.3 LACK OF ACCESS TO DIAGNOSIS SERVICES IN LMICS

11 MARKET LANDSCAPE

  • 11.1 MARKET OVERVIEW
  • 11.2 MARKET SIZE & FORECAST
  • 11.3 FIVE FORCES ANALYSIS
    • 11.3.1 THREAT OF NEW ENTRANTS
    • 11.3.2 BARGAINING POWER OF SUPPLIERS
    • 11.3.3 BARGAINING POWER OF BUYERS
    • 11.3.4 THREAT OF SUBSTITUTES
    • 11.3.5 COMPETITIVE RIVALRY

12 PRODUCTS

  • 12.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 12.2 MARKET OVERVIEW
  • 12.3 VIRAL TRANSPORT MEDIA
    • 12.3.1 MARKET OVERVIEW
    • 12.3.2 MARKET SIZE & FORECAST
    • 12.3.3 MARKET BY GEOGRAPHY
  • 12.4 UNIVERSAL TRANSPORT MEDIA
    • 12.4.1 MARKET OVERVIEW
    • 12.4.2 MARKET SIZE & FORECAST
    • 12.4.3 MARKET BY GEOGRAPHY
  • 12.5 MOLECULAR TRANSPORT MEDIA
    • 12.5.1 MARKET OVERVIEW
    • 12.5.2 MARKET SIZE & FORECAST
    • 12.5.3 MARKET BY GEOGRAPHY

13 USAGE

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 DIAGNOSIS
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 MARKET BY GEOGRAPHY
  • 13.4 PRE-CLINICAL TESTING
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 MARKET BY GEOGRAPHY

14 INDICATION

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 INFLUENZA & COVID-19
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 MARKET BY GEOGRAPHY
  • 14.4 HERPES SIMPLEX VIRUS
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 MARKET BY GEOGRAPHY
  • 14.5 RESPIRATORY SYNCYTIAL VIRUS (RSV)
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST
    • 14.5.3 MARKET BY GEOGRAPHY
  • 14.6 VARICELLA-ZOSTER
    • 14.6.1 MARKET OVERVIEW
    • 14.6.2 MARKET SIZE & FORECAST
    • 14.6.3 MARKET BY GEOGRAPHY
  • 14.7 OTHERS
    • 14.7.1 MARKET OVERVIEW
    • 14.7.2 MARKET SIZE & FORECAST
    • 14.7.3 MARKET BY GEOGRAPHY

15 END-USER

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 LABS
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 MARKET BY GEOGRAPHY
  • 15.4 HOSPITALS & CLINICS
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 MARKET BY GEOGRAPHY
  • 15.5 OTHERS
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
    • 15.5.3 MARKET BY GEOGRAPHY

16 GEOGRAPHY

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
  • 17.3 PRODUCT
    • 17.3.1 MARKET SIZE & FORECAST
  • 17.4 USAGE
    • 17.4.1 MARKET SIZE & FORECAST
  • 17.5 INDICATION
    • 17.5.1 MARKET SIZE & FORECAST
  • 17.6 END-USER
    • 17.6.1 MARKET SIZE & FORECAST
  • 17.7 KEY COUNTRIES
    • 17.7.1 US: MARKET SIZE & FORECAST
    • 17.7.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
  • 18.3 PRODUCT
    • 18.3.1 MARKET SIZE & FORECAST
  • 18.4 USAGE
    • 18.4.1 MARKET SIZE & FORECAST
  • 18.5 INDICATION
    • 18.5.1 MARKET SIZE & FORECAST
  • 18.6 END-USER
    • 18.6.1 MARKET SIZE & FORECAST
  • 18.7 KEY COUNTRIES
    • 18.7.1 UK: MARKET SIZE & FORECAST
    • 18.7.2 FRANCE: MARKET SIZE & FORECAST
    • 18.7.3 ITALY: MARKET SIZE & FORECAST
    • 18.7.4 GERMANY: MARKET SIZE & FORECAST
    • 18.7.5 SPAIN: MARKET SIZE & FORECAST

19 APAC

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
  • 19.3 PRODUCT
    • 19.3.1 MARKET SIZE & FORECAST
  • 19.4 USAGE
    • 19.4.1 MARKET SIZE & FORECAST
  • 19.5 INDICATION
    • 19.5.1 MARKET SIZE & FORECAST
  • 19.6 END-USER
    • 19.6.1 MARKET SIZE & FORECAST
  • 19.7 KEY COUNTRIES
    • 19.7.1 CHINA: MARKET SIZE & FORECAST
    • 19.7.2 JAPAN: MARKET SIZE & FORECAST
    • 19.7.3 INDIA: MARKET SIZE & FORECAST
    • 19.7.4 AUSTRALIA: MARKET SIZE & FORECAST
    • 19.7.5 SOUTH KOREA: MARKET SIZE & FORECAST

20 LATIN AMERICA

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
  • 20.3 PRODUCT
    • 20.3.1 MARKET SIZE & FORECAST
  • 20.4 USAGE
    • 20.4.1 MARKET SIZE & FORECAST
  • 20.5 INDICATION
    • 20.5.1 MARKET SIZE & FORECAST
  • 20.6 END-USER
    • 20.6.1 MARKET SIZE & FORECAST
  • 20.7 KEY COUNTRIES
    • 20.7.1 BRAZIL: MARKET SIZE & FORECAST
    • 20.7.2 MEXICO: MARKET SIZE & FORECAST
    • 20.7.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
  • 21.3 PRODUCT
    • 21.3.1 MARKET SIZE & FORECAST
  • 21.4 USAGE
    • 21.4.1 MARKET SIZE & FORECAST
  • 21.5 INDICATION
    • 21.5.1 MARKET SIZE & FORECAST
  • 21.6 USAGE
    • 21.6.1 MARKET SIZE & FORECAST
  • 21.7 END-USER
    • 21.7.1 MARKET SIZE & FORECAST
  • 21.8 KEY COUNTRIES
    • 21.8.1 TURKEY: MARKET SIZE & FORECAST
    • 21.8.2 SAUDI ARABIA: MARKET SIZE & FORECAST
    • 21.8.3 SOUTH AFRICA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

  • 22.1 COMPETITION OVERVIEW
  • 22.2 MARKET SHARE ANALYSIS

23 KEY COMPANY PROFILES

  • 23.1 BD (BECTON DICKINSON)
    • 23.1.1 BUSINESS OVERVIEW
    • 23.1.2 PRODUCT OFFERINGS
    • 23.1.3 KEY STRATEGIES
    • 23.1.4 KEY STRENGTHS
    • 23.1.5 KEY OPPORTUNITIES
  • 23.2 HARDY DIAGNOSTICS
    • 23.2.1 BUSINESS OVERVIEW
    • 23.2.2 PRODUCT OFFERINGS
    • 23.2.3 KEY STRATEGIES
    • 23.2.4 KEY STRENGTHS
    • 23.2.5 KEY OPPORTUNITIES
  • 23.3 HIMEDIA LABORATORIES
    • 23.3.1 BUSINESS OVERVIEW
    • 23.3.2 PRODUCT OFFERINGS
    • 23.3.3 KEY STRATEGIES
    • 23.3.4 KEY STRENGTHS
    • 23.3.5 KEY OPPORTUNITIES
  • 23.4 LABORATORY CORPORATION OF AMERICA
    • 23.4.1 BUSINESS OVERVIEW
    • 23.4.2 PRODUCT OFFERINGS
    • 23.4.3 KEY STRATEGIES
    • 23.4.4 KEY STRENGTHS
    • 23.4.5 KEY OPPORTUNITIES
  • 23.5 PURITAN MEDICAL PRODUCTS
    • 23.5.1 BUSINESS OVERVIEW
    • 23.5.2 PRODUCT OFFERINGS
    • 23.5.3 KEY STRATEGIES
    • 23.5.4 KEY STRENGTHS
    • 23.5.5 KEY OPPORTUNITIES
  • 23.6 THERMO FISHER SCIENTIFIC
    • 23.6.1 BUSINESS OVERVIEW
    • 23.6.2 PRODUCT OFFERINGS
    • 23.6.3 KEY STRATEGIES
    • 23.6.4 KEY STRENGTHS
  • 23.7 VIRCELL
    • 23.7.1 BUSINESS OVERVIEW
    • 23.7.2 PRODUCT OFFERINGS
    • 23.7.3 KEY STRATEGIES
    • 23.7.4 KEY STRENGTHS
    • 23.7.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

  • 24.1 AB MEDICAL
    • 24.1.1 BUSINESS OVERVIEW
    • 24.1.2 PRODUCT OFFERINGS
  • 24.2 ACCUGENE USA
    • 24.2.1 BUSINESS OVERVIEW
    • 24.2.2 PRODUCT OFFERINGS
  • 24.3 APICAL SCIENTIFIC
    • 24.3.1 BUSINESS OVERVIEW
    • 24.3.2 PRODUCT OFFERING
  • 24.4 AZOOKA LABS
    • 24.4.1 BUSINESS OVERVIEW
    • 24.4.2 PRODUCT OFFERING
  • 24.5 BIOMED DIAGNOSTICS
    • 24.5.1 BUSINESS OVERVIEW
    • 24.5.2 PRODUCT OFFERINGS
  • 24.6 BIOBOAVISTA
    • 24.6.1 BUSINESS OVERVIEW
    • 24.6.2 PRODUCT OFFERINGS
  • 24.7 BIOGENEX LABORATORIES
    • 24.7.1 BUSINESS OVERVIEW
    • 24.7.2 PRODUCT OFFERINGS
  • 24.8 BIOLOGIX GROUP
    • 24.8.1 BUSINESS OVERVIEW
    • 24.8.2 PRODUCT OFFERINGS
  • 24.9 BIOCOMMA
    • 24.9.1 BUSINESS OVERVIEW
    • 24.9.2 PRODUCT OFFERINGS
  • 24.10 CHARM SCIENCES
    • 24.10.1 BUSINESS OVERVIEW
    • 24.10.2 PRODUCT OFFERINGS
  • 24.11 CREATIVE LIFE SCIENCES CO. LTD.
    • 24.11.1 BUSINESS OVERVIEW
    • 24.11.2 PRODUCT OFFERINGS
  • 24.12 CITOTEST LABWARE MANUFACTURING
    • 24.12.1 BUSINESS OVERVIEW
    • 24.12.2 PRODUCT OFFERINGS
  • 24.13 CPT MEDICAL
    • 24.13.1 BUSINESS OVERVIEW
    • 24.13.2 PRODUCT OFFERINGS
  • 24.14 COPAN DIAGNOSTIC INC.
    • 24.14.1 BUSINESS OVERVIEW
    • 24.14.2 PRODUCT OFFERINGS
  • 24.15 DIASORIN MOLECULAR
    • 24.15.1 BUSINESS OVERVIEW
    • 24.15.2 PRODUCT OFFERINGS
  • 24.16 EKF DIAGNOSTICS HOLDINGS PLC
    • 24.16.1 BUSINESS OVERVIEW
    • 24.16.2 PRODUCT OFFERINGS
  • 24.17 ENSOL BIOSCIENCES
    • 24.17.1 BUSINESS OVERVIEW
    • 24.17.2 PRODUCT OFFERINGS
  • 24.18 GEMINI BIOPRODUCTS
    • 24.18.1 BUSINESS OVERVIEW
    • 24.18.2 PRODUCT OFFERINGS
  • 24.19 GENERAL BIOLOGICS
    • 24.19.1 BUSINESS OVERVIEW
    • 24.19.2 PRODUCT OFFERINGS
  • 24.20 GENTUERI
    • 24.20.1 BUSINESS OVERVIEW
    • 24.20.2 PRODUCT OFFERINGS
  • 24.21 GENESIS LIFETECH MARKETING
    • 24.21.1 BUSINESS OVERVIEW
    • 24.21.2 PRODUCT OFFERINGS
  • 24.22 HAN CHANG MEDIC
    • 24.22.1 BUSINESS OVERVIEW
    • 24.22.2 PRODUCT OFFERINGS
  • 24.23 HEBEI CHAORAN MEDICAL INSTRUMENTS
    • 24.23.1 BUSINESS OVERVIEW
    • 24.23.2 PRODUCT OFFERING
  • 24.24 KSL DIAGNOSTICS
    • 24.24.1 BUSINESS OVERVIEW
    • 24.24.2 PRODUCT OFFERING
  • 24.25 LUCENCE HEALTH
    • 24.25.1 BUSINESS OVERVIEW
    • 24.25.2 PRODUCT OFFERINGS
  • 24.26 LAUNCHWORKS
    • 24.26.1 BUSINESS OVERVIEW
    • 24.26.2 PRODUCT OFFERING
  • 24.27 LIOFILCHEM
    • 24.27.1 BUSINESS OVERVIEW
    • 24.27.2 PRODUCT OFFERING
  • 24.28 MEDICAL WIRE & EQUIPMENT (MWE)
    • 24.28.1 BUSINESS OVERVIEW
    • 24.28.2 PRODUCT OFFERINGS
  • 24.29 MIRACLEAN TECHNOLOGY
    • 24.29.1 BUSINESS OVERVIEW
    • 24.29.2 PRODUCT OFFERINGS
  • 24.30 METADESIGN SOLUTIONS
    • 24.30.1 BUSINESS OVERVIEW
    • 24.30.2 PRODUCT OFFERINGS
  • 24.31 MANILA HEALTHTEK
    • 24.31.1 BUSINESS OVERVIEW
    • 24.31.2 PRODUCT OFFERING
  • 24.32 MATTEK
    • 24.32.1 BUSINESS OVERVIEW
    • 24.32.2 PRODUCT OFFERING
  • 24.33 NODFORD INTERNATIONAL
    • 24.33.1 BUSINESS OVERVIEW
    • 24.33.2 PRODUCT OFFERING
  • 24.34 STARPLEX SCIENTIFIC
    • 24.34.1 BUSINESS OVERVIEW
    • 24.34.2 PRODUCT OFFERINGS
  • 24.35 SANSURE BIOTECH
    • 24.35.1 BUSINESS OVERVIEW
    • 24.35.2 PRODUCT OFFERINGS
  • 24.36 TITAN BIOTECH
    • 24.36.1 BUSINESS OVERVIEW
    • 24.36.2 PRODUCT OFFERINGS
  • 24.37 VEGAS BIOTECH
    • 24.37.1 BUSINESS OVERVIEW
    • 24.37.2 PRODUCT OFFERING
  • 24.38 ZYBIO
    • 24.38.1 BUSINESS OVERVIEW
    • 24.38.2 PRODUCT OFFERING

25 REPORT SUMMARY

  • 25.1 KEY TAKEAWAYS
  • 25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

  • 26.1 MARKET BY GEOGRAPHY
  • 26.2 MARKET BY PRODUCT
  • 26.3 MARKET BY USAGE
  • 26.4 MARKET BY INDICATION
  • 26.5 MARKET BY END-USER
  • 26.6 PRODUCT: MARKET BY GEOGRAPHY
    • 26.6.1 VIRAL TRANSPORT MEDIA: MARKET BY GEOGRAPHY
    • 26.6.2 UNIVERSAL TRANSPORT MEDIA: MARKET BY GEOGRAPHY
    • 26.6.3 MOLECULAR TRANSPORT MEDIA: MARKET BY GEOGRAPHY
  • 26.7 USAGE: MARKET BY GEOGRAPHY
    • 26.7.1 DIAGNOSIS: MARKET BY GEOGRAPHY
    • 26.7.2 PRE-CLINICAL TESTING: MARKET BY GEOGRAPHY
  • 26.8 INDICATION: MARKET BY GEOGRAPHY
    • 26.8.1 INFLUENZA & COVID-19: MARKET BY GEOGRAPHY
    • 26.8.2 HERPES: MARKET BY GEOGRAPHY
    • 26.8.3 RESPIRATORY SYNCYTIAL VIRUS: MARKET BY GEOGRAPHY
    • 26.8.4 VARICELLA ZOSTER VIRUS: MARKET BY GEOGRAPHY
    • 26.8.5 OTHER INDICATIONS: MARKET BY GEOGRAPHY
  • 26.9 END-USER: MARKET BY GEOGRAPHY
    • 26.9.1 LABS: MARKET BY GEOGRAPHY
    • 26.9.2 HOSPITALS & CLINICS: MARKET BY GEOGRAPHY
    • 26.9.3 OTHER INDICATION: MARKET BY GEOGRAPHY

27 APPENDIX

  • 27.1 ABBREVIATIONS